Cancer biomarkers: minimal and noninvasive early diagnosis and prognosis
"According to the American Cancer Society report, "by 2030, the global cancer burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths." Early diagnosis improves treatment efficacy and quality of life as well as reduces the cost for disease management...
Gespeichert in:
| Weitere Verfasser: | , , , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Boca Raton ; London ; New York
CRC Press, Taylor & Francis Group
[2014]
|
| Schlagworte: | |
| Zusammenfassung: | "According to the American Cancer Society report, "by 2030, the global cancer burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths." Early diagnosis improves treatment efficacy and quality of life as well as reduces the cost for disease management. However, the development of molecular markers for early cancer diagnosis is always a challenge. Some fundamental principles in medical practice are (a) primum non nocere, a Latin phrase that means "first, do no harm," and (b) even when a patient's prognosis is poor, the physician must do his or her best for improving quality of the patient's life. Therefore, noninvasive or minimally invasive cancer diagnostic methods are of choice that can avoid complications of biopsy and other unfavorable impacts on patient's health. In this context, patients' easily collectable biospecimens such as blood, serum, plasma, urine, stool, sputum, saliva, etc., based molecular markers having high specificity and sensitivity in early diagnosis are emerging rapidly and in many instances such markers are also emerging as next-generation prognostic indicators and personalized therapeutics and precision medicine. Several patents have been filed and/or granted on such markers, and a number of health-care companies and authorities currently use or focus on the development of such markers. The significance of clinical validation approaches of several markers has been discussed in different chapters. This book, Cancer Biomarkers: Noninvasive Early Diagnosis and Prognosis, reflects the rapid expansion of important scientific, technological, clinical, and translational aspects of noninvasive or minimally invasive molecular cancer biomarkers and their applications along with other conventional markers".. |
| Beschreibung: | Includes bibliographical references and index |
| Beschreibung: | xxiii, 949 Seiten Illustrationen, Diagramme |
| ISBN: | 9781466584280 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV044488081 | ||
| 003 | DE-604 | ||
| 005 | 20171027 | ||
| 007 | t | ||
| 008 | 170914s2014 xxua||| |||| 00||| eng d | ||
| 020 | |a 9781466584280 |c hardback : £193.00 |9 978-1-4665-8428-0 | ||
| 035 | |a (OCoLC)871570181 | ||
| 035 | |a (DE-599)BVBBV044488081 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c US | ||
| 049 | |a DE-29 | ||
| 050 | 0 | |a RC270.3.T84 | |
| 082 | 0 | |a 616.99/4 |2 23 | |
| 245 | 1 | 0 | |a Cancer biomarkers |b minimal and noninvasive early diagnosis and prognosis |c edited by Debmalya Barh, Angelo Carpi, Mukesh Verma, Mehmet Gunduz |
| 264 | 1 | |a Boca Raton ; London ; New York |b CRC Press, Taylor & Francis Group |c [2014] | |
| 264 | 4 | |c © 2014 | |
| 300 | |a xxiii, 949 Seiten |b Illustrationen, Diagramme | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 520 | |a "According to the American Cancer Society report, "by 2030, the global cancer burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths." Early diagnosis improves treatment efficacy and quality of life as well as reduces the cost for disease management. However, the development of molecular markers for early cancer diagnosis is always a challenge. Some fundamental principles in medical practice are (a) primum non nocere, a Latin phrase that means "first, do no harm," and (b) even when a patient's prognosis is poor, the physician must do his or her best for improving quality of the patient's life. Therefore, noninvasive or minimally invasive cancer diagnostic methods are of choice that can avoid complications of biopsy and other unfavorable impacts on patient's health. In this context, patients' easily collectable biospecimens such as blood, serum, plasma, urine, stool, sputum, saliva, etc., based molecular markers having high specificity and sensitivity in early diagnosis are emerging rapidly and in many instances such markers are also emerging as next-generation prognostic indicators and personalized therapeutics and precision medicine. Several patents have been filed and/or granted on such markers, and a number of health-care companies and authorities currently use or focus on the development of such markers. The significance of clinical validation approaches of several markers has been discussed in different chapters. This book, Cancer Biomarkers: Noninvasive Early Diagnosis and Prognosis, reflects the rapid expansion of important scientific, technological, clinical, and translational aspects of noninvasive or minimally invasive molecular cancer biomarkers and their applications along with other conventional markers".. | ||
| 650 | 4 | |a Tumor markers | |
| 650 | 4 | |a Cancer |x Diagnosis | |
| 650 | 4 | |a Cancer |x Treatment | |
| 650 | 4 | |a Tumor Markers, Biological | |
| 650 | 4 | |a Early Detection of Cancer | |
| 650 | 4 | |a Neoplasms | |
| 650 | 4 | |a Neoplasms | |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 700 | 1 | |a Barh, Debmalya |0 (DE-588)1075646146 |4 edt | |
| 700 | 1 | |a Carpi, Angelo |4 edt | |
| 700 | 1 | |a Verma, Mukesh |d ca. 20./21. Jh. |0 (DE-588)124872891 |4 edt | |
| 700 | 1 | |a Gunduz, Mehmet |4 edt | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029888097 | ||
Datensatz im Suchindex
| _version_ | 1804177831018627072 |
|---|---|
| any_adam_object | |
| author2 | Barh, Debmalya Carpi, Angelo Verma, Mukesh ca. 20./21. Jh Gunduz, Mehmet |
| author2_role | edt edt edt edt |
| author2_variant | d b db a c ac m v mv m g mg |
| author_GND | (DE-588)1075646146 (DE-588)124872891 |
| author_facet | Barh, Debmalya Carpi, Angelo Verma, Mukesh ca. 20./21. Jh Gunduz, Mehmet |
| building | Verbundindex |
| bvnumber | BV044488081 |
| callnumber-first | R - Medicine |
| callnumber-label | RC270 |
| callnumber-raw | RC270.3.T84 |
| callnumber-search | RC270.3.T84 |
| callnumber-sort | RC 3270.3 T84 |
| callnumber-subject | RC - Internal Medicine |
| ctrlnum | (OCoLC)871570181 (DE-599)BVBBV044488081 |
| dewey-full | 616.99/4 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4 |
| dewey-search | 616.99/4 |
| dewey-sort | 3616.99 14 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03299nam a2200457 c 4500</leader><controlfield tag="001">BV044488081</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20171027 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">170914s2014 xxua||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781466584280</subfield><subfield code="c">hardback : £193.00</subfield><subfield code="9">978-1-4665-8428-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)871570181</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044488081</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC270.3.T84</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/4</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cancer biomarkers</subfield><subfield code="b">minimal and noninvasive early diagnosis and prognosis</subfield><subfield code="c">edited by Debmalya Barh, Angelo Carpi, Mukesh Verma, Mehmet Gunduz</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boca Raton ; London ; New York</subfield><subfield code="b">CRC Press, Taylor & Francis Group</subfield><subfield code="c">[2014]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xxiii, 949 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">"According to the American Cancer Society report, "by 2030, the global cancer burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths." Early diagnosis improves treatment efficacy and quality of life as well as reduces the cost for disease management. However, the development of molecular markers for early cancer diagnosis is always a challenge. Some fundamental principles in medical practice are (a) primum non nocere, a Latin phrase that means "first, do no harm," and (b) even when a patient's prognosis is poor, the physician must do his or her best for improving quality of the patient's life. Therefore, noninvasive or minimally invasive cancer diagnostic methods are of choice that can avoid complications of biopsy and other unfavorable impacts on patient's health. In this context, patients' easily collectable biospecimens such as blood, serum, plasma, urine, stool, sputum, saliva, etc., based molecular markers having high specificity and sensitivity in early diagnosis are emerging rapidly and in many instances such markers are also emerging as next-generation prognostic indicators and personalized therapeutics and precision medicine. Several patents have been filed and/or granted on such markers, and a number of health-care companies and authorities currently use or focus on the development of such markers. The significance of clinical validation approaches of several markers has been discussed in different chapters. This book, Cancer Biomarkers: Noninvasive Early Diagnosis and Prognosis, reflects the rapid expansion of important scientific, technological, clinical, and translational aspects of noninvasive or minimally invasive molecular cancer biomarkers and their applications along with other conventional markers"..</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tumor markers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Diagnosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tumor Markers, Biological</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Early Detection of Cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barh, Debmalya</subfield><subfield code="0">(DE-588)1075646146</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Carpi, Angelo</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verma, Mukesh</subfield><subfield code="d">ca. 20./21. Jh.</subfield><subfield code="0">(DE-588)124872891</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gunduz, Mehmet</subfield><subfield code="4">edt</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029888097</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV044488081 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:54:19Z |
| institution | BVB |
| isbn | 9781466584280 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029888097 |
| oclc_num | 871570181 |
| open_access_boolean | |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | xxiii, 949 Seiten Illustrationen, Diagramme |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | CRC Press, Taylor & Francis Group |
| record_format | marc |
| spelling | Cancer biomarkers minimal and noninvasive early diagnosis and prognosis edited by Debmalya Barh, Angelo Carpi, Mukesh Verma, Mehmet Gunduz Boca Raton ; London ; New York CRC Press, Taylor & Francis Group [2014] © 2014 xxiii, 949 Seiten Illustrationen, Diagramme txt rdacontent n rdamedia nc rdacarrier Includes bibliographical references and index "According to the American Cancer Society report, "by 2030, the global cancer burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths." Early diagnosis improves treatment efficacy and quality of life as well as reduces the cost for disease management. However, the development of molecular markers for early cancer diagnosis is always a challenge. Some fundamental principles in medical practice are (a) primum non nocere, a Latin phrase that means "first, do no harm," and (b) even when a patient's prognosis is poor, the physician must do his or her best for improving quality of the patient's life. Therefore, noninvasive or minimally invasive cancer diagnostic methods are of choice that can avoid complications of biopsy and other unfavorable impacts on patient's health. In this context, patients' easily collectable biospecimens such as blood, serum, plasma, urine, stool, sputum, saliva, etc., based molecular markers having high specificity and sensitivity in early diagnosis are emerging rapidly and in many instances such markers are also emerging as next-generation prognostic indicators and personalized therapeutics and precision medicine. Several patents have been filed and/or granted on such markers, and a number of health-care companies and authorities currently use or focus on the development of such markers. The significance of clinical validation approaches of several markers has been discussed in different chapters. This book, Cancer Biomarkers: Noninvasive Early Diagnosis and Prognosis, reflects the rapid expansion of important scientific, technological, clinical, and translational aspects of noninvasive or minimally invasive molecular cancer biomarkers and their applications along with other conventional markers".. Tumor markers Cancer Diagnosis Cancer Treatment Tumor Markers, Biological Early Detection of Cancer Neoplasms (DE-588)4143413-4 Aufsatzsammlung gnd-content Barh, Debmalya (DE-588)1075646146 edt Carpi, Angelo edt Verma, Mukesh ca. 20./21. Jh. (DE-588)124872891 edt Gunduz, Mehmet edt |
| spellingShingle | Cancer biomarkers minimal and noninvasive early diagnosis and prognosis Tumor markers Cancer Diagnosis Cancer Treatment Tumor Markers, Biological Early Detection of Cancer Neoplasms |
| subject_GND | (DE-588)4143413-4 |
| title | Cancer biomarkers minimal and noninvasive early diagnosis and prognosis |
| title_auth | Cancer biomarkers minimal and noninvasive early diagnosis and prognosis |
| title_exact_search | Cancer biomarkers minimal and noninvasive early diagnosis and prognosis |
| title_full | Cancer biomarkers minimal and noninvasive early diagnosis and prognosis edited by Debmalya Barh, Angelo Carpi, Mukesh Verma, Mehmet Gunduz |
| title_fullStr | Cancer biomarkers minimal and noninvasive early diagnosis and prognosis edited by Debmalya Barh, Angelo Carpi, Mukesh Verma, Mehmet Gunduz |
| title_full_unstemmed | Cancer biomarkers minimal and noninvasive early diagnosis and prognosis edited by Debmalya Barh, Angelo Carpi, Mukesh Verma, Mehmet Gunduz |
| title_short | Cancer biomarkers |
| title_sort | cancer biomarkers minimal and noninvasive early diagnosis and prognosis |
| title_sub | minimal and noninvasive early diagnosis and prognosis |
| topic | Tumor markers Cancer Diagnosis Cancer Treatment Tumor Markers, Biological Early Detection of Cancer Neoplasms |
| topic_facet | Tumor markers Cancer Diagnosis Cancer Treatment Tumor Markers, Biological Early Detection of Cancer Neoplasms Aufsatzsammlung |
| work_keys_str_mv | AT barhdebmalya cancerbiomarkersminimalandnoninvasiveearlydiagnosisandprognosis AT carpiangelo cancerbiomarkersminimalandnoninvasiveearlydiagnosisandprognosis AT vermamukesh cancerbiomarkersminimalandnoninvasiveearlydiagnosisandprognosis AT gunduzmehmet cancerbiomarkersminimalandnoninvasiveearlydiagnosisandprognosis |